Key Opinion Leaders for Europe and the US join the Surfers the day after the first MASH drug, Rezdiffra, was approved, to discuss how they heard the news and what kinds of patients they envision as initial targets.
This conversation focuses on why it will be challenging to use currently-available NITs to stage patients with advanced MASH fibrosis (F2/F3) accurately with current test options.
This conversation on the new MASLD nomenclature rollout has two major elements: discussing the role of Allied Health Providers and looking more broadly at the ongoing rollout process.
In this discussion, Jeff Lazarus, who oversaw the global Delphi process that led to the final new MASLD nomenclature, describe how a Delphi process works and some of its strengths and weaknesses here.
Maru Rinella, Jeff Lazarus and Meena Bansal, all key players in the new MASLD nomenclature process join patient advocate Mike Betel, Louise Campbell and Roger Green to discuss the process, the benefits of the outcome, and where things go from here.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to describe their priority MASH programs for 2024.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the role that MASLD patient advocates and others are likely to play in MASH drug access decisions, along with education and informational processes.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the challenges in patient access and education that will follow the first MASH drug approval. expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss their expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Leading MASLD patient advocates Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fatty Liver Foundation, Jeff McIntyre of the Global Liver Institute, and Milan Mishkevikj of the European Liver Patients Association join Louise Campbell and Roger Green to share their vision of changes in the MASH world in 2024 along with each organization’s hopes, concerns and plans. The discussion covers the advocates’ hopes and concerns for the year as well as the programs and efforts each considers top priority.
